Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects is a research paper published in Brain (2015). On theSindex it has a DataRank of 0.745. It has been cited 143 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.745
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIA NIH HHS
Grant: AG1210
NIA NIH HHS
Grant: R21 AG043885
NINDS NIH HHS
Grant: P50 NS053488
NHLBI NIH HHS
Grant: R01 HL118624
NCATS NIH HHS
Grant: UL1 TR001079
NIA NIH HHS
Grant: AG022374
NIA NIH HHS
Grant: AG13616
NIA NIH HHS
Grant: K23 AG042856
NIA NIH HHS
Grant: P01 AG017586
NIA NIH HHS
Grant: P30 AG008051
NIA NIH HHS
Grant: R01 AG022374
NIA NIH HHS
Grant: U01 AG024904
NIA NIH HHS
Grant: P50 AG005134
NIA NIH HHS
Grant: P01 AG036694
NIA NIH HHS
Grant: P30 AG013846
NIA NIH HHS
Grant: P01 AG032953
NIA NIH HHS
Grant: P50 AG016976
NIA NIH HHS
Grant: P50 AG005146
NIA NIH HHS
Grant: U19 AG033655
CIHR
CIHR
FWCI
11.07
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
Additional file 1 of Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
Additional file 1 of Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
Additional file 1 of Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
Additional file 1 of Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
Additional file 1 of Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
Additional file 1 of Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults
Additional file 1 of Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults
Additional file 1 of Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study
Additional file 1 of Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study
Additional file 2 of Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study
Additional file 2 of Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study
Additional file 2 of Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
Additional file 2 of Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts